A case report of vitiligo following toripalimab therapy for a patient with metastatic melanoma
- 16 November 2022
- journal article
- letter
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (12), e15973
- https://doi.org/10.1111/dth.15973
Abstract
No abstract availableFunding Information
- Wu Jieping Medical Foundation (320.6750.19088‐33)
This publication has 6 references indexed in Scilit:
- Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II TrialClinical Cancer Research, 2020
- Toripalimab-Induced Dermatomyositis in a Patient with Metastatic MelanomaDermatology and Therapy, 2020
- Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic reviewTherapeutic Advances in Medical Oncology, 2020
- Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanomaZeitschrift für Krebsforschung und Klinische Onkologie, 2018
- Vitiligo after immune checkpoint inhibitor therapy in a woman with metastatic melanomaJournal of Cancer Research and Practice, 2018
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationThe New England Journal of Medicine, 2015